In rat xenografts of MLL-rearranged leukemia, continuous intravenous (IV) infusion of EPZ5676 as a single agent resulted in dose-dependent tumor regression with a concomitant reduction in H3K79 methylation and consequential transcriptional repression of MLL target genes in the tumors [33]. This evidence concerns the gene KMT2A and neoplasm.